Formycon AG vs. Regeneron Pharmaceuticals, Inc.
Explore the PTAB proceeding IPR2025-00233 filed by Formycon AG on 2024-12-02. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2025-00233
Filing Date
2024-12-02
Accorded Filing Date
2024-12-02
Institution Decision Date
2025-06-02
Last Modified Date
2025-07-03
Proceeding Type
IPR
Termination Date
2025-06-02
Trial Status
Institution Denied
Parties & Counsel
Petitioner
Formycon AG
Represented By
Fogel, Louiset alPatent Owner / Respondent
Regeneron Pharmaceuticals, Inc.
Represented By
Berl, Davidet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
1 Total
Proceeding Status
Institution Denied
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (1)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 41408 | David Marsh | +1 202-942-5068 |
| 48001 | Thomas Triolo | +1 914-847-1612 |
| 48921 | Stephen Gaudet | +1 914-847-7376 |
| 50370 | Neil Miyamoto | +1 914-847-7175 |
| 50437 | Frank Cottingham | +1 914-593-1116 |
| 58583 | Brian Cocca | +1 914-847-1421 |
| 58714 | Ilona Gont | +1 914-847-1304 |
| 59668 | Brandon Schurter | +1 914-847-7000 |
Global Patent Family Cross-Litigation Radar
CasLoc 360ยฐ Radar 12 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| ๐บ๐ธ United States | US 11,084,865 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 81,448,406 P | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 7,608,261 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 7,807,164 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 8,092,803 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 8,481,046 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 8,802,107 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 9,340,594 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 9,914,763 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,400,025 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,464,992 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,066,458 B2 | US Continuation / Sibling | View Official Patent → |
Fresenius Kabi SwissBioSim GmbH et al. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. REGENERON PHARMACEUTICALS, INC.
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Chengdu Kanghong Biotechnology Co., Ltd. et al. v. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc.
Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, CO., LTD.